ORIGINAL ARTICLESRole of methylenetetrahydrofolate reductase A1298C polymorphism in cerebral venous thrombosisFekih-Mrissa, Najibaa; Klai, Sarraa; Mrad, Meriema; Zaouali, Jamelb; Sayeh, Aychaa; Nsiri, Brahima; Gritli, Nasreddinea; Mrissa, RidhabAuthor Information aLaboratory of Molecular Biology, Department of Hematology bDepartment of Neurology, Military Hospital, Tunis, Tunisia Correspondence to Najiba Fekih Mrissa, PhD, Laboratory of Molecular Biology, Department of Hematology, Military Hospital, Montfleury, 1008 Tunis, Tunisia Tel: +21 62 251 0488; fax: +21 67 076 2084; e-mail: email@example.com Received 15 May, 2012 Revised 8 June, 2012 Accepted 15 June, 2012 Blood Coagulation & Fibrinolysis: March 2013 - Volume 24 - Issue 2 - p 118-119 doi: 10.1097/MBC.0b013e32835707cd Buy Metrics Abstract The association between the methylenetetrahydrofolate reductase (MTHFR) gene and cerebral venous thrombosis (CVT) remains controversial. This study principally investigated the potential role of the MTHFR A1298C variant and CVT. The genotyping of the A1298C variant of the MTHFR gene was performed in 35 CVT patients and 200 healthy controls. The frequency of A1298C genotype among CVT patients was significantly higher compared with controls (P < 10−3), suggesting an association between this polymorphism and CVT. To our knowledge, there are no previous reports assessing the correlation between the MTHFR A1298C variant and CVT. Large study populations would be required to understand the contribution of this marker in the risk of CVT. © 2013 Lippincott Williams & Wilkins, Inc.